Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Another trial enrolled participants described as having SO; however, the intervention combined structured exercise with nutritional supplementation, precluding isolation of the independent effect of vitamin D.

Source: Study selection and phenotype alignment. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Systematic review.

Systematic review

Uses explicit methods to identify, assess and summarise research on a defined question.

Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Vitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Vitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials

Systematic review · Frontiers in Nutrition · 2026

Original publication title

Vitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials

Cristina Russo; Maria Stella Valle; Sofia Surdo; Michele Tuttobene; Maria Teresa Cambria; Lucia Malaguarnera

Copyright © 2026 Russo, Valle, Surdo, Tuttobene, Cambria and Malaguarnera.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Despite compelling mechanistic convergence, randomized interventional evidence in strictly defined sarcopenic obesity populations is currently lacking. Future RCTs must adopt phenotype-defined enrollment strategies integrating adiposity, muscle dysfunction, and mechanistic endpoints to determine whether micronutrient signaling can meaningfully modify outcomes in SO.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Sarcopenic obesity (SO) is an inflammatory-metabolic condition characterized by the coexistence of excess adiposity and impaired skeletal muscle mass and function. Vitamin D and resveratrol modulate regulatory pathways implicated in SO pathophysiology, including NF-κB signaling, PGC-1α, mitochondrial regulation, and redox balance. Whether this mechanistic rationale has translated into phenotype-defined randomized clinical trials remains unclear.

Source: Background

Abstract: What methods does the paper describe?

We conducted a systematic dual-track search across PubMed, Scopus, and Web of Science to identify randomized controlled trials (RCTs) evaluating isolated vitamin D or resveratrol supplementation in adults with explicitly defined sarcopenic obesity or meeting implicit SO phenotype criteria, defined as the concurrent presence of adiposity and objective muscle impairment at baseline. Trials lacking confirmation of both components at enrollment were excluded. Risk of bias was assessed using Cochrane RoB 2.0.

Source: Methods

Abstract: Systematic review registration

Abstract: Results

The search retrieved five records (PubMed n = 5; Scopus n = 0; Web of Science n = 0). Following full-text assessment, none met eligibility criteria requiring baseline confirmation of both adiposity and sarcopenia together with isolated vitamin D or resveratrol supplementation (n = 0). Retrieved RCTs in related populations did not simultaneously require adiposity and muscle impairment as enrollment criteria. As a result, no phenotype-defined interventional evidence specific to sarcopenic obesity was identified.

Source: Results

Abstract: Conclusion

Despite compelling mechanistic convergence, randomized interventional evidence in strictly defined sarcopenic obesity populations is currently lacking. Future RCTs must adopt phenotype-defined enrollment strategies integrating adiposity, muscle dysfunction, and mechanistic endpoints to determine whether micronutrient signaling can meaningfully modify outcomes in SO.

Source: Conclusion
Authors’ abstract

Background

Sarcopenic obesity (SO) is an inflammatory-metabolic condition characterized by the coexistence of excess adiposity and impaired skeletal muscle mass and function. Vitamin D and resveratrol modulate regulatory pathways implicated in SO pathophysiology, including NF-κB signaling, PGC-1α, mitochondrial regulation, and redox balance. Whether this mechanistic rationale has translated into phenotype-defined randomized clinical trials remains unclear.

Methods

We conducted a systematic dual-track search across PubMed, Scopus, and Web of Science to identify randomized controlled trials (RCTs) evaluating isolated vitamin D or resveratrol supplementation in adults with explicitly defined sarcopenic obesity or meeting implicit SO phenotype criteria, defined as the concurrent presence of adiposity and objective muscle impairment at baseline. Trials lacking confirmation of both components at enrollment were excluded. Risk of bias was assessed using Cochrane RoB 2.0.

Results

The search retrieved five records (PubMed n = 5; Scopus n = 0; Web of Science n = 0). Following full-text assessment, none met eligibility criteria requiring baseline confirmation of both adiposity and sarcopenia together with isolated vitamin D or resveratrol supplementation (n = 0). Retrieved RCTs in related populations did not simultaneously require adiposity and muscle impairment as enrollment criteria. As a result, no phenotype-defined interventional evidence specific to sarcopenic obesity was identified.

Conclusion

Despite compelling mechanistic convergence, randomized interventional evidence in strictly defined sarcopenic obesity populations is currently lacking. Future RCTs must adopt phenotype-defined enrollment strategies integrating adiposity, muscle dysfunction, and mechanistic endpoints to determine whether micronutrient signaling can meaningfully modify outcomes in SO.

Systematic review registration

https://www.crd.york.ac.uk/PROSPERO/view/CRD420261307248, identifier PROSPERO (CRD420261307248).

Publication and source details

Original title: Vitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials

Cristina Russo; Maria Stella Valle; Sofia Surdo; Michele Tuttobene; Maria Teresa Cambria; Lucia Malaguarnera

Frontiers in Nutrition · 2026

* Correspondence: Lucia Malaguarnera, lucmal@unict.itCopyright © 2026 Russo, Valle, Surdo, Tuttobene, Cambria and Malaguarnera.2026Russo, Valle, Surdo, Tuttobene, Cambria and Malaguarnerahttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the PNRR: “Health Extended ALliance for Innovative Therapies, Advanced Lab-research, and Integrated Approaches of Precision” CUP: E63C22002080006 and University of Catania (grant “Fondi di Ateneo 2024-2026; University of Catania, PIA.CE.RI, linea Open Access”).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T10:33:21.322535+00:00

DOI: 10.3389/fnut.2026.1818450 · PMC13216041